Most-Downgraded StocksMost-DowngradedNASDAQ:ACAD ACADIA Pharmaceuticals (ACAD) Stock Price, News & Analysis → Central Banks Preparing for US Dollar Collapse? (From Behind the Markets) (Ad) Free ACAD Stock Alerts $18.49 +0.29 (+1.59%) (As of 03/28/2024 ET) Add Compare Share Share Today's Range$18.05▼$18.5050-Day Range$17.79▼$28.1552-Week Range$17.56▼$33.99Volume1.53 million shsAverage Volume1.87 million shsMarket Capitalization$3.05 billionP/E RatioN/ADividend YieldN/APrice Target$36.12 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get ACADIA Pharmaceuticals alerts: Email Address ACADIA Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.80 Rating ScoreUpside/Downside95.3% Upside$36.12 Price TargetShort InterestBearish6.45% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment-0.28Based on 16 Articles This WeekInsider TradingSelling Shares$841,461 Sold Last QuarterProj. Earnings Growth84.38%From $0.64 to $1.18 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.18 out of 5 starsMedical Sector188th out of 938 stocksPharmaceutical Preparations Industry74th out of 417 stocks 4.4 Analyst's Opinion Consensus RatingACADIA Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on 12 buy ratings, 3 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $36.12, ACADIA Pharmaceuticals has a forecasted upside of 95.3% from its current price of $18.49.Amount of Analyst CoverageACADIA Pharmaceuticals has been the subject of 10 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 2.0 Short Interest Percentage of Shares Shorted6.45% of the outstanding shares of ACADIA Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverACADIA Pharmaceuticals has a short interest ratio ("days to cover") of 5.8.Change versus previous monthShort interest in ACADIA Pharmaceuticals has recently decreased by 1.67%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldACADIA Pharmaceuticals does not currently pay a dividend.Dividend GrowthACADIA Pharmaceuticals does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ACAD. Previous Next 2.1 News and Social Media Coverage News SentimentACADIA Pharmaceuticals has a news sentiment score of -0.28. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 16 news articles for ACADIA Pharmaceuticals this week, compared to 6 articles on an average week.Search Interest20 people have searched for ACAD on MarketBeat in the last 30 days. This is an increase of 5% compared to the previous 30 days.MarketBeat Follows14 people have added ACADIA Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 56% compared to the previous 30 days. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, ACADIA Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $841,461.00 in company stock.Percentage Held by Insiders27.50% of the stock of ACADIA Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions96.71% of the stock of ACADIA Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.9 Earnings and Valuation Earnings GrowthEarnings for ACADIA Pharmaceuticals are expected to grow by 84.38% in the coming year, from $0.64 to $1.18 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of ACADIA Pharmaceuticals is -48.66, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of ACADIA Pharmaceuticals is -48.66, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioACADIA Pharmaceuticals has a P/B Ratio of 7.03. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Behind the MarketsCentral Banks Preparing for US Dollar Collapse?China is spearheading this blatant de-dollarization push, dominating the physical gold market through massive central bank buying. Their ultimate goal? Ditching the greenback in favor of local BRICS currencies.Find out how you can protect yourself now >>> About ACADIA Pharmaceuticals Stock (NASDAQ:ACAD)ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-101 whixh is in Phase III for the treatment of hyperphagia in Prader-Willi syndrome; ACP-204 which is in Phase II for the treatment of Alzheimer's disease psychosis; ACP-2591 that is in Phase I for Rett syndrome and Fragile X syndrome; preclinical antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms. It has a license agreement with Neuren Pharmaceuticals Limited to develop and commercialize trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.Read More ACAD Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ACAD Stock News HeadlinesMarch 28, 2024 | insidertrades.comInsider Selling: ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) COO Sells 5,140 Shares of StockMarch 29, 2024 | americanbankingnews.comACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) CEO Sells $317,080.60 in StockMarch 29, 2024 | Behind the Markets (Ad)Central Banks Preparing for US Dollar Collapse?China is spearheading this blatant de-dollarization push, dominating the physical gold market through massive central bank buying. Their ultimate goal? Ditching the greenback in favor of local BRICS currencies.March 28, 2024 | uk.investing.comThese Overlooked Mid-Cap Gems Are Ripe for a ReboundMarch 28, 2024 | finance.yahoo.comACADIA Pharmaceuticals Inc CEO Stephen Davis Sells 17,714 SharesMarch 27, 2024 | americanbankingnews.comJPMorgan Chase & Co. Cuts ACADIA Pharmaceuticals (NASDAQ:ACAD) Price Target to $25.00March 26, 2024 | americanbankingnews.comACADIA Pharmaceuticals (NASDAQ:ACAD) Hits New 12-Month Low on Analyst DowngradeMarch 25, 2024 | markets.businessinsider.comAnalysts Are Bullish on Top Healthcare Stocks: Immatics (IMTX), Vor Biopharma (VOR)March 29, 2024 | Behind the Markets (Ad)Central Banks Preparing for US Dollar Collapse?China is spearheading this blatant de-dollarization push, dominating the physical gold market through massive central bank buying. Their ultimate goal? Ditching the greenback in favor of local BRICS currencies.March 22, 2024 | americanbankingnews.comACADIA Pharmaceuticals Inc. to Post FY2024 Earnings of $0.64 Per Share, Zacks Research Forecasts (NASDAQ:ACAD)March 20, 2024 | americanbankingnews.comResearch Analysts Offer Predictions for ACADIA Pharmaceuticals Inc.'s Q1 2024 Earnings (NASDAQ:ACAD)March 19, 2024 | stocknews.com4 Cutting-Edge Pharma Stocks for Portfolio DiversificationMarch 18, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Ionis Pharmaceuticals (IONS), Edwards Lifesciences (EW) and Aveanna Healthcare Holdings (AVAH)March 15, 2024 | businesswire.comAcadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)March 14, 2024 | investorplace.com3 Pharma Stocks to Sell in March Before They Crash & BurnMarch 13, 2024 | markets.businessinsider.comGrabar Law Office Investigates Claims on Behalf of Shareholders of Acadia Pharmaceuticals Inc. (ACAD)March 13, 2024 | finance.yahoo.comAcadia Pharmaceuticals to Participate in the UBS Virtual CNS DayMarch 13, 2024 | seekingalpha.comEvaluating Acadia's Market Position Following Pimavanserin's Clinical SetbackMarch 13, 2024 | markets.businessinsider.comACADIA Pharmaceuticals Sinks After Schizophrenia Drug Failed In Late-stage StudyMarch 13, 2024 | msn.comThese Stocks Are Moving the Most Today: Oracle, Acadia Pharmaceuticals, Vail Resorts, and MoreMarch 12, 2024 | finance.yahoo.comAcadia drug fails schizophrenia trial, setting back company’s expansion plansMarch 12, 2024 | investopedia.comAcadia Pharmaceuticals Stock Sinks After Schizophrenia Drug Study Falls ShortMarch 12, 2024 | seekingalpha.comAcadia Pharmaceuticals: Post Pimavanserin Study Setback Selloff May ContinueMarch 12, 2024 | marketwatch.comAcadia Pharmaceuticals Shares Fall Premarket After Study FailureMarch 12, 2024 | msn.comTrial Setback For Acadia Pharmaceuticals' Late-Stage Schizophrenia Trial: DetailsMarch 12, 2024 | msn.comThese Stocks Are Moving the Most Today: Oracle, Nvidia, Acadia Pharmaceuticals, Archer Daniels, On Holding, Vail Resorts, and MoreMarch 12, 2024 | finance.yahoo.comAcadia Hits 11-Month Low After Outsized Placebo Effect Torpedoes Schizophrenia StudySee More Headlines Receive ACAD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ACADIA Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/27/2024Today3/28/2024Next Earnings (Estimated)5/13/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:ACAD CUSIPN/A CIK1070494 Webwww.acadia-pharm.com Phone(858) 558-2871Fax858-558-2872Employees597Year FoundedN/APrice Target and Rating Average Stock Price Target$36.12 High Stock Price Target$95.00 Low Stock Price Target$25.00 Potential Upside/Downside+95.3%Consensus RatingModerate Buy Rating Score (0-4)2.80 Research Coverage15 Analysts Profitability EPS (Most Recent Fiscal Year)($0.38) Trailing P/E RatioN/A Forward P/E Ratio28.89 P/E GrowthN/ANet Income$-61,290,000.00 Net Margins-8.44% Pretax Margin-7.03% Return on Equity-15.67% Return on Assets-9.15% Debt Debt-to-Equity RatioN/A Current Ratio2.42 Quick Ratio2.28 Sales & Book Value Annual Sales$726.44 million Price / Sales4.19 Cash FlowN/A Price / Cash FlowN/A Book Value$2.63 per share Price / Book7.03Miscellaneous Outstanding Shares164,770,000Free Float119,460,000Market Cap$3.05 billion OptionableOptionable Beta0.40 Investing Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free Report Key ExecutivesMr. Stephen R. Davis J.D. (Age 63)President, CEO & Director Comp: $1.46MMr. Mark C. Schneyer (Age 49)Executive VP & CFO Comp: $701.03kMr. Brendan P. Teehan (Age 55)Executive VP, COO & Head of Commercial Comp: $724.31kMr. James K. Kihara (Age 43)VP, Chief Accounting Officer & Corporate Controller Dr. Douglas J. Williamson M.D. (Age 62)Executive VP & Head of Research & Development Dr. Kevin R. Oliver Ph.D. (Age 54)Senior VP & Chief Business Officer Ms. Stephanie KimSenior Vice President of Regulatory AffairsMs. Erika Parker ZavodSenior Vice President of Strategy, Planning, Research & DevelopmentMs. Kimberly J. Manhard (Age 64)Senior Vice President of Global Strategic Planning & Execution More ExecutivesKey CompetitorsHUTCHMEDNASDAQ:HCMCrinetics PharmaceuticalsNASDAQ:CRNXIndiviorNASDAQ:INDVArvinasNASDAQ:ARVNMorphoSysNASDAQ:MORView All CompetitorsInsiders & InstitutionsStephen DavisSold 17,714 sharesTotal: $317,080.60 ($17.90/share)Brendan TeehanSold 5,140 sharesTotal: $92,006.00 ($17.90/share)Mark C SchneyerSold 5,434 sharesTotal: $97,268.60 ($17.90/share)Vanguard Group Inc.Sold 220,731 shares on 3/11/2024Ownership: 8.130%Fisher Asset Management LLCBought 143,054 shares on 3/5/2024Ownership: 0.087%View All Insider TransactionsView All Institutional Transactions ACAD Stock Analysis - Frequently Asked Questions Should I buy or sell ACADIA Pharmaceuticals stock right now? 15 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ACADIA Pharmaceuticals in the last year. There are currently 3 hold ratings and 12 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" ACAD shares. View ACAD analyst ratings or view top-rated stocks. What is ACADIA Pharmaceuticals' stock price target for 2024? 15 equities research analysts have issued 1 year price objectives for ACADIA Pharmaceuticals' stock. Their ACAD share price targets range from $25.00 to $95.00. On average, they expect the company's share price to reach $36.12 in the next year. This suggests a possible upside of 95.3% from the stock's current price. View analysts price targets for ACAD or view top-rated stocks among Wall Street analysts. How have ACAD shares performed in 2024? ACADIA Pharmaceuticals' stock was trading at $31.31 at the beginning of the year. Since then, ACAD stock has decreased by 40.9% and is now trading at $18.49. View the best growth stocks for 2024 here. When is ACADIA Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, May 13th 2024. View our ACAD earnings forecast. How were ACADIA Pharmaceuticals' earnings last quarter? ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) issued its earnings results on Tuesday, February, 27th. The biopharmaceutical company reported $0.28 earnings per share for the quarter, missing the consensus estimate of $0.32 by $0.04. The biopharmaceutical company earned $231.04 million during the quarter, compared to the consensus estimate of $223.79 million. ACADIA Pharmaceuticals had a negative trailing twelve-month return on equity of 15.67% and a negative net margin of 8.44%. ACADIA Pharmaceuticals's revenue for the quarter was up 69.3% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($0.26) EPS. What ETFs hold ACADIA Pharmaceuticals' stock? ETFs with the largest weight of ACADIA Pharmaceuticals (NASDAQ:ACAD) stock in their portfolio include iShares Neuroscience and Healthcare ETF (IBRN), ALPS Medical Breakthroughs ETF (SBIO), Invesco Biotechnology & Genome ETF (PBE), First Trust NYSE Arca Biotechnology Index Fund (FBT), Virtus LifeSci Biotech Products ETF (BBP), SPDR S&P Biotech ETF (XBI), Principal Healthcare Innovators ETF (BTEC) and Direxion Daily S&P Biotech Bull 3x Shares (LABU). What guidance has ACADIA Pharmaceuticals issued on next quarter's earnings? ACADIA Pharmaceuticals issued an update on its FY 2024 earnings guidance on Tuesday, February, 27th. The company provided EPS guidance of for the period. The company issued revenue guidance of $930.0 million-$1.0 billion, compared to the consensus revenue estimate of $965.1 million. What is Steve Davis' approval rating as ACADIA Pharmaceuticals' CEO? 8 employees have rated ACADIA Pharmaceuticals Chief Executive Officer Steve Davis on Glassdoor.com. Steve Davis has an approval rating of 88% among the company's employees. What other stocks do shareholders of ACADIA Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other ACADIA Pharmaceuticals investors own include Micron Technology (MU), NVIDIA (NVDA), Gilead Sciences (GILD), Sarepta Therapeutics (SRPT), Pfizer (PFE), Tesla (TSLA), Alibaba Group (BABA), Amarin (AMRN), Advanced Micro Devices (AMD) and Exelixis (EXEL). Who are ACADIA Pharmaceuticals' major shareholders? ACADIA Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (8.16%), Vanguard Group Inc. (8.13%), RTW Investments LP (6.85%), Price T Rowe Associates Inc. MD (3.15%), Palo Alto Investors LP (1.47%) and First Trust Advisors LP (1.08%). Insiders that own company stock include Austin D Kim, Austin D Kim, Brendan Teehan, Bros Advisors Lp Baker, Elena Ridloff, James Kihara, Laura Brege, Mark C Schneyer, Srdjan R Stankovic, Srdjan R Stankovic and Stephen Davis. View institutional ownership trends. How do I buy shares of ACADIA Pharmaceuticals? Shares of ACAD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ACAD) was last updated on 3/29/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsTop Project Outperforms BTC in 2023…Crypto 101 Media“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryAI Cracks Open Largest Untapped Energy Reserve on EarthBanyan Hill PublishingThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyOnly a fool would buy Nvidia today… Porter & CompanyMost important medical advance in 100 yearsThe Oxford Club Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ACADIA Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.